Drug Approval | June 13, 2026
UK approves Wegovy pill in major shift in obesity treatment options
Approval is based on results from the phase 3 OASIS 4 clinical trial
Approval is based on results from the phase 3 OASIS 4 clinical trial
The company said data from multiple VESPER studies show the peptide delivered meaningful weight loss, favorable tolerability, and the possibility of a first-in-class monthly injection format
The move signals a major expansion in access to next-generation weight-loss therapies
The move marks one of the most significant coverage expansions yet in obesity care, bringing FDA-approved treatment options further into mainstream insurance plans rather than out-of-pocket reach
Clinical guidelines and expert consensus recommend 1.2–1.5 g/kg/day protein intake during therapy to help preserve muscle mass
The conference brought together over 500 doctors and 150 nutritionists to discuss emerging obesity-related challenges
GoodRx at a starting price of $149 per month—aligned with the lowest available discounted cash price at launch. The rollout includes nationwide pharmacy access
As demand for GLP-1 therapies explodes, India’s drug regulator moves to curb advertising amid rising concerns over misuse, access, and long-term impact
The approval is backed by results from Lilly’s ATTAIN clinical trial program, which showed significant weight loss among participants
Zydus has developed an innovative Semaglutide Injection (15 mg/3 ml) in a prefilled cartridge administered using a patient-friendly reusable pen for which the company has exclusive rights
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
